Gut Microbiota and Metabolic Disorders

다국어 초록 (Multilingual Abstract)

Gut microbiota plays critical physiological roles in the energy extraction and in the control of local or systemic immunity. Gut microbiota and its disturbance also appear to be involved in the pathogenesis of diverse diseases including metabolic disorders, gastrointestinal diseases, cancer, etc. In the metabolic point of view, gut microbiota can modulate lipid accumulation, lipopolysaccharide content and the production of short-chain fatty acids that affect food intake, inflammatory tone, or insulin signaling. Several strategies have been developed to change gut microbiota such as prebiotics, probiotics, certain antidiabetic drugs or fecal microbiota transplantation, which have diverse effects on body metabolism and on the development of metabolic disorders.

참고문헌 (Reference)

1 Vrieze A, "Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome" 143 : 913-916, 2012

2 Delaere F, "The role of sodium-coupled glucose co-transporter 3 in the satiety effect of portal glucose sensing" 2 : 47-53, 2012

3 Kimura I, "The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43" 4 : 1829-, 2013

4 Backhed F, "The gut microbiota as an environmental factor that regulates fat storage" 101 : 15718-15723, 2004

5 Guarner F, "Studies with inulin-type fructans on intestinal infections, permeability, and inflammation" 137 (137): 2568S-2571S, 2007

6 Cani PD, "Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia" 50 : 2374-2383, 2007

7 Tazoe H, "Roles of short-chain fatty acids receptors, GPR41 and GPR43 on colonic functions" 59 (59): 251-262, 2008

8 Everard A, "Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice" 60 : 2775-2786, 2011

9 Ewaschuk J, "Probiotic bacteria prevent hepatic damage and maintain colonic barrier function in a mouse model of sepsis" 46 : 841-850, 2007

10 Roberfroid M, "Prebiotic effects: metabolic and health benefits" 104 (104): 1-63, 2010

11 Conterno L, "Obesity and the gut microbiota: does up-regulating colonic fermentation protect against obesity and metabolic disease?" 6 : 241-260, 2011

12 Ley RE, "Obesity alters gut microbial ecology" 102 : 11070-11075, 2005

13 Shan M, "Mucus enhances gut homeostasis and oral tolerance by delivering immunoregulatory signals" 342 : 447-453, 2013

14 De Vadder F, "Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits" 156 : 84-96, 2014

15 Everard A, "Microbiome of prebiotic-treated mice reveals novel targets involved in host response during obesity" 8 : 2116-2130, 2014

16 Cabreiro F, "Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism" 153 : 228-239, 2013

17 Cani PD, "Metabolic endotoxemia initiates obesity and insulin resistance" 56 : 1761-1772, 2007

18 Backhed F, "Mechanisms underlying the resistance to diet-induced obesity in germ-free mice" 104 : 979-984, 2007

19 de Kort S, "Leaky gut and diabetes mellitus: what is the link?" 12 : 449-458, 2011

20 Amar J, "Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment" 3 : 559-572, 2011

21 Moreira AP, "Influence of a high-fat diet on gut microbiota, intestinal permeability and metabolic endotoxaemia" 108 : 801-809, 2012

22 Brun P, "Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis" 292 : 518-525, 2007

23 Cani PD, "Improvement of glucose tolerance and hepatic insulin sensitivity by oligofructose requires a functional glucagon-like peptide 1 receptor" 55 : 1484-1490, 2006

24 Backhed F, "Host-bacterial mutualism in the human intestine" 307 : 1915-1920, 2005

25 Cani PD, "Gut microbiota fermentation of prebiotics increases satietogenic and incretin gut peptide production with consequences for appetite sensation and glucose response after a meal" 90 : 1236-1243, 2009

26 Lakhan SE, "Gut microbiota and sirtuins in obesity-related inflammation and bowel dysfunction" 9 : 202-, 2011

27 Karlsson FH, "Gut metagenome in European women with normal, impaired and diabetic glucose control" 498 : 99-103, 2013

28 Alvarez-Castro P, "Ghrelin in obesity, physiological and pharmacological considerations" 13 : 541-552, 2013

29 Delzenne N, "Gastrointestinal targets of appetite regulation in humans" 11 : 234-250, 2010

30 van Nood E, "Duodenal infusion of donor feces for recurrent Clostridium difficile" 368 : 407-415, 2013

31 Turnbaugh PJ, "Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome" 3 : 213-223, 2008

32 Cani PD, "Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice" 57 : 1470-1481, 2008

33 Cani PD, "Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability" 58 : 1091-1103, 2009

34 Turnbaugh PJ, "An obesity-associated gut microbiome with increased capacity for energy harvest" 444 : 1027-1031, 2006

35 Shin NR, "An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice" 63 : 727-735, 2014

36 Qin J, "A metagenome-wide association study of gut microbiota in type 2 diabetes" 490 : 55-60, 2012

37 Qin J, "A human gut microbial gene catalogue established by metagenomic sequencing" 464 : 59-65, 2010